INmune Bio, Inc. (INMB)

11.29 +0.45 (+4.15%) At close: 04:00PM EDT

INmune Bio, Inc.

225 NE Mizner Blvd.
Suite 640
Boca Raton, FL 33432
United States
858 964 3720
https://www.inmunebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Raymond Joseph Tesi M.D.	Co-Founder, President, CEO, Chief Medical Officer & Chairman	500.5k	N/A	1956
Mr. David J. Moss M.B.A.	CFO, Treasurer & Secretary	394.9k	N/A	1970
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.	Chief Scientific Officer & Chief Manufacturing Officer	150.24k	N/A	1963
Mr. Joshua S. Schoonover Esq.	General Counsel	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Corporate governance

INmune Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.